Dannenberg Hilde, Dinjens Winand N M, Abbou Mustaffa, Van Urk Hero, Pauw Bernard K H, Mouwen Diane, Mooi Wolter J, de Krijger Ronald R
Department of Pathology, Josephine Nefkens Institute, Erasmus Medical Center, 1738 Rotterdam, the Netherlands.
Clin Cancer Res. 2002 Jul;8(7):2061-6.
Recently, familial paraganglioma (PGL) was shown to be caused bymutations in the gene encoding succinate dehydrogenase subunit D (SDHD). However, the prevalence of SDHD mutations in apparently sporadic PGL is unknown. We studied the frequency and spectrum of germ-line and somatic SDHD mutations in patients with parasympathetic PGL. EXPERIMENTAL DESIGH: We studied 57 unselected patients who developed parasympathetic PGLs (n = 105 tumors) and who were treated between 1987 and 1999 at the Erasmus MC (Rotterdam, the Netherlands). Thirty-eight (67%) of these patients (n = 51 tumors) lacked a family history of parasympathetic PGL. We used conformation-dependent gel electrophoresis and sequence determination analysis of germ-line and tumor DNA to identify SDHD mutations. We compared the clinical and molecular characteristics of sporadic and hereditary PGLs.
Three different SDHD germ-line mutations were identified in 32 of the 57 (56%) patients. These included 19 of 19 (100%) patients with familial PGL and also 13 of 38 (34%) patients with apparently sporadic PGL. All three mutations were characterized as missense mutations (D92Y, L95P, and L139P) in highly conserved regions of the SDHD gene and were not observed in 200 control alleles. No somatic mutations were found.
Germ-line mutations of the SDHD gene are present in a significant number of patients with apparently sporadic parasympathetic PGL. Somatic SDHD mutations do not play a significant role in the sporadic form of this tumor. Genetic testing for SDHD germ-line mutations should be considered for every patient presenting with this tumor, even if a personal or family history of PGL is absent, to allow appropriate clinical management.
最近研究表明,家族性副神经节瘤(PGL)是由编码琥珀酸脱氢酶亚基D(SDHD)的基因突变引起的。然而,在明显散发的PGL中SDHD突变的发生率尚不清楚。我们研究了副交感神经PGL患者中种系和体细胞SDHD突变的频率及谱。
我们研究了57例未经选择的发生副交感神经PGL的患者(共105个肿瘤),这些患者于1987年至1999年在伊拉斯姆斯医学中心(荷兰鹿特丹)接受治疗。其中38例(67%)患者(共51个肿瘤)无副交感神经PGL家族史。我们采用构象依赖性凝胶电泳及种系和肿瘤DNA的序列测定分析来鉴定SDHD突变。我们比较了散发型和遗传型PGL的临床及分子特征。
57例患者中有32例(56%)鉴定出三种不同的SDHD种系突变。其中包括19例(100%)家族性PGL患者,以及38例中13例(34%)明显散发型PGL患者。所有三种突变均为SDHD基因高度保守区域的错义突变(D92Y、L95P和L139P),在200个对照等位基因中未观察到。未发现体细胞突变。
大量明显散发的副交感神经PGL患者存在SDHD基因种系突变。体细胞SDHD突变在该肿瘤的散发型中不起重要作用。对于每一位患有此肿瘤的患者,即使无PGL个人或家族史,也应考虑进行SDHD种系突变的基因检测,以便进行适当的临床管理。